Bls Pharmaceuticals (ASX:BLS) — Material Events
ASX:BLS · 4 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
BLS Pharmaceuticals Doubles Revenue and Profit in FY26, Secures $50m German ContractMedium
BLS Pharmaceuticals reports record FY26 revenue and profit, secures $50 million German supply deal, expands international manufacturing
31 Aug 2026
·Annual Financial Results
·90
BLS Pharmaceuticals Hits Record $75m Revenue, Locks $50m German Supply DealHigh
BLS Pharmaceuticals reports record FY26 revenue and EBITDA, secures major international supply deals, and advances manufacturing expansion
27 July 2026
·Quarterly Activities Report
·90
BLS reports record Q1 revenue as Scotland facility nears regulatory reviewHigh
BLS reports record Q1 FY27 revenue and reaffirms full-year guidance
15 Oct 2026
·Quarterly Activities Report
·86
BLS Pharmaceuticals Posts Record $22.5m Q4 Revenue, Expands Global Manufacturing FootprintMedium
BLS Pharmaceuticals reports record Q4 FY2026 revenue and cash flow, expands international GMP manufacturing platform
30 July 2026
·Investor Presentation
·85
No articles in this tier for the last 12 months.
Market Mentions
4
- appeared in market wrap coverage
These are market wrap articles where Bls Pharmaceuticals (ASX:BLS) was mentioned. They reflect broader market coverage, not company-specific announcements.
Market Wrap - Week 36 (31 Aug -> 4 Sept) 2026
5 Sept 2026
Healthcare Wrap - Week 36 (31 Aug -> 4 Sept) 2026
5 Sept 2026
Market Wrap - Week 31 (27 July -> 31 July) 2026
1 Aug 2026
Healthcare Wrap - Week 31 (27 July -> 31 July) 2026
1 Aug 2026